“25 years ago we were one of the first companies to enter the field of molecular diagnosis and genetic identification in Spain. During this time, we have been able to innovate and adapt to change, shaping our business around the technological developments and needs of the moment”. Said our Director Dr. Rosario Cospedal in the event organized to commemorate the 25th anniversary of the company and the opening of new headquarters in Madrid.
In addition to Ms. Cospedal, we had other speakers such as: Dr. Santiago Ramon y Cajal Agüeras, head of the Department of Pathology of the Hospital Vall d’Hebron in Barcelona; Dr. Rafael Lopez Lopez, Head of Oncology Hospital of Santiago de Compostela; Castrodeza Dr. José Javier Sanz, General Director of Health and Quality and Innovation of the Ministry of Health.Social Services and Equality; Dr. José María Fdez Sousa-Faro, President of the Zeltia Group.; and Dr. Ruben Moreno, General Secretery of Health.
“For the Group, it is an honour to have a company such as GENOMICA, capable of leading scientific advances in Spain in the field of DNA technology and the conquering of new markets with its range of products and services in the field of molecular diagnosis and genetic identification . It is a pleasure for all to celebrate a 25th anniversary that highlights the excellent work of the team and its daily capacity to improve” said our president, Dr. José María Fernández Sousa-Faro.
25 years of milestones:
In GENOMICA we focus on in vitro molecular diagnostics in the field of infectious diseases and oncology, as well as genetic identification services. In the words of our CEO, “Today, GENOMICA invests more than 25% of it’s resources in R + D + i, whose main lines are:
• Design of new products following the CLART® line
• Detecting tumor mutations in liquid biopsy,
• Improving our existing molecular diagnostic platform
• New diagnostics based on nanotechnology. ”
Similarly, he noted that “moving to the new facilities represents a contribution to promoting this research activity thanks to the expansion and construction of new laboratories and last generation clean rooms.”
Throughout these 25 years, we have excelled in the field of genetic identification by collaboration with the Spanish State Security Forces, as well as technology transfer and assembly of laboratories in Spain (Guardia Civil and Scientific Police), Morocco, Panama, El Salvador, Venezuela and Angola.
Regarding the field of molecular diagnostics, we wish to emphasize the development of our own technology, CLART® based on low-density microarrays, creating a line of oncologic molecular diagnostics, and the international expansion of the company. Today, we are present in 37 countries, with a subsidiary in Sweden, a representative office in China, and two sales representatives in Brazil and UAE, and every year we sell about 350,000 test in addition to services given from our facilities.
We collaborate with pharmacutical companies in Spain and some Asian countries for the realization of their oncological drugs companion diagnostic. In the field of infectious diseases and technological development, we maintain collaborative projects with private companies and research groups in the Philippines, Sweden, Turkey, France, Germany, UK and Spain.
Contributions of the molecular diagnostic in clinical practice:
“The XXI century is called the century of precision medicine”. With these words Dr. Rafael Lopez Lopez explained how we have witnessed a paradigm shift in the treatment and management of complex diseases, some chronic, caused by the interaction of genetic and environmental factors. “To arrive to a proper diagnosis, we need molecular data from the patient” pointed the medical expert, who added that “molecular medicine try to give each patient the treatment most likely to be effective with the fewer toxicities”.
Oncology experts say that thanks to precision medicine they have been able to evolve in the treatement of patients with cancer. “Today we can’t successfully treat some tumors without genetic testing, molecular profile or information on different characteristics. We are confident that in the next 5-10 years their use will be essential in the treatment and monitoring of 100% of the tumors, ” Dr Rafael Lopez concluded.
Meanwhile, Dr. Santiago Ramon y Cajal, who was also present at the event, stressed the importance of “tumor diagnosis being made in multidisciplinary teams with clinical personal, radiologists, pathologists and molecular biologists. It is essential the integration and coordination of all of them. ”
From his experience, the application of tumor diagnosis is increasingly being complemented with molecular studies in cancer patients, which will allow to describe multiple oncogenic alterations when the diagnosis is made and to monitorize the presence of these changes during the progression of the disease and after the anti-tumoral therapy.
During these phases is highlighted the importance which is shown by the liquid biopsy. For these reasons, Dr. Ramón y Cajal defends the importance of investigating the human genome and the many biochemical ways that might be affected: “The molecular and biochemical knowledge is key to the diagnosis, monitoring and aplication of specific treatment to many tumors and, quite possibly, to most of them on a medium term, as the knowledge of oncogenic keys and targets advances”.